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Introduction
Skeletal muscle undergoes atrophy, or wasting, characterized 
by a reduction in fiber cross-sectional area (CSA), protein con-
tent, and strength, in several chronic conditions, including   
cancer, chronic heart failure, cystic fibrosis, AIDS, and after 
high dose treatment with glucocorticoids (Glass, 2005; Sandri, 
2008).  Furthermore,  skeletal  muscle  also  undergoes  atrophy 
when its level of neuromuscular activity is reduced, including in 
the conditions of denervation, unloading, or immobilization 
(Jackman and Kandarian, 2004), and also in settings of func-
tional denervation as in the elderly patients with sarcopenia 
(Macaluso and De Vito, 2004).
Inflammation plays a pivotal role in skeletal muscle wast-
ing, especially in chronic disease states (Späte and Schulze, 2004; 
Argilés et al., 2005). Elevated levels of proinflammatory cytokines 
precede the onset of muscle wasting in sepsis-induced cachexia, 
AIDS, chronic heart failure, and cancer (Späte and Schulze, 
2004; Argilés et al., 2005; Li et al., 2008). Consistent with its 
recognized role as a mediator of inflammation, we have recently 
reported that TNF-like weak inducer of apoptosis (TWEAK) is 
a powerful skeletal muscle–wasting cytokine (Dogra et al., 
2007a). The addition of TWEAK to cultured myotubes or 
chronic administration in mice causes significant loss of skel-
etal muscle mass (Dogra et al., 2007a). However, the physiolog-
ical significance of TWEAK in vivo and the conditions in   
which TWEAK acts as a mediator of muscle-wasting remain   
largely unknown.
S
keletal  muscle  atrophy  occurs  in  a  variety  of   
clinical settings, including cachexia, disuse, and   
denervation. Inflammatory cytokines have been 
shown to be mediators of cancer cachexia; however, the 
role  of  cytokines  in  denervation-  and  immobilization- 
induced skeletal muscle loss remains unknown. In this 
study, we demonstrate that a single cytokine, TNF-like 
weak inducer of apoptosis (TWEAK), mediates skeletal 
muscle  atrophy  that  occurs  under  denervation  condi-
tions. Transgenic expression of TWEAK induces atrophy, 
fibrosis,  fiber-type  switching,  and  the  degradation  of 
muscle proteins. Importantly, genetic ablation of TWEAK 
decreases the loss of muscle proteins and spared fiber 
cross-sectional area, muscle mass, and strength after de-
nervation.  Expression  of  the  TWEAK  receptor  Fn14   
(fibroblast growth factor–inducible receptor 14) and not 
the cytokine is significantly increased in muscle upon   
denervation, demonstrating an unexpected inside-out 
signaling pathway; the receptor up-regulation allows   
for TWEAK activation of nuclear factor B, causing an 
increase in the expression of the E3 ubiquitin ligase 
MuRF1. This study reveals a novel mediator of skeletal 
muscle  atrophy  and  indicates  that  the  TWEAK–Fn14   
system  is  an  important  target  for  preventing  skeletal 
muscle wasting.
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skeletal muscle of TWEAK-Tg mice, mRNA levels of TWEAK 
were  assessed  in  different  tissues  of  3-mo-old  TWEAK-Tg 
and control mice by quantitative real-time PCR (QRT-PCR)   
assays. An approximately four- to sixfold increase in the level 
of  TWEAK  mRNA  was  consistently  observed  in  skeletal 
muscle and an 1.5-fold increase in the cardiac muscle of the 
TWEAK-Tg compared with control mice (Fig. 1 A). No signifi-
cant difference in mRNA levels was observed in liver or spleen   
(Fig. 1 A). We also measured the protein levels of TWEAK in 
tissue extracts and serum using an ELISA assay kit. As shown 
in Fig. 1 B, the levels of TWEAK protein were approximately 
three- to fourfold higher in the skeletal muscle of TWEAK-Tg 
mice compared with littermate control mice (TWEAK-Tg,   
2.88 ± 0.05 ng/mg vs. littermate control, 0.72 ± 0.03 ng/mg 
protein in tibialis anterior [TA] muscle extracts). In addition 
to transgenic mice, we also used TWEAK-KO mice (Maecker   
et al., 2005). TWEAK-KO mice did not show any overt pheno-
type. Although body and different organ weights (e.g., brain, 
liver, kidney, heart, lung, and thymus) were comparable be-
tween control and TWEAK-KO mice, a significant increase 
in the number of natural killer cells in secondary lymphoid   
organs of TWEAK-KO mice compared with wild-type mice has 
been previously reported (Maecker et al., 2005).
TWEAK functions by binding to Fn14 (fibroblast growth 
factor–inducible  receptor  14)  in  skeletal  muscle  (Girgenrath 
et al., 2006; Dogra et al., 2007b). We examined whether over-
expression or genetic ablation of TWEAK in 3-mo-old mice   
affects the expression of Fn14 in skeletal muscle. The transcript 
levels of Fn14 in skeletal muscle of TWEAK-Tg mice were 
comparable with control mice (Fig. 1 C). However, mRNA lev-
els of Fn14 were found to be increased by 1.6-fold in skeletal 
muscle of TWEAK-KO mice compared with controls (Fig. 1 C), 
suggesting the possibility of a compensatory mechanism that 
might be activated in the absence of the Fn14 ligand TWEAK. 
Transcript levels of TNF, IL-1, and IL-6 in TWEAK-Tg mice 
were comparable with controls, indicating the absence of any 
nonspecific inflammation in TWEAK-Tg mice (Fig. 1 D). In 
addition, serum levels of CK in TWEAK-Tg and TWEAK-KO 
mice were also comparable with control mice, suggesting that 
overexpression or genetic ablation of TWEAK does not cause 
any overt muscle pathology in mice (Fig. 1 E).
Transgenic overexpression of TWEAK 
causes muscle atrophy in vivo
We  next  studied  the  in  vivo  effects  of TWEAK  on  skeletal 
muscle. Hematoxylin and eosin (H&E) staining did not show any   
major structural differences in skeletal muscle between control,   
TWEAK-Tg, and TWEAK-KO mice at 1 or 3 mo of age (un-
published data). However, differences in skeletal muscle structure   
became apparent after 4–5 mo, especially in soleus muscle. 
Soleus muscle of 6-mo-old TWEAK-Tg mice showed reduced 
fiber size (Fig. 2 A). Masson’s trichrome staining of muscle 
sections revealed increased levels of collagen fibers in soleus   
muscle of 6-mo-old TWEAK-Tg mice compared with control 
mice (Fig. 2 A, middle). Immunohistochemical analysis and 
Western blotting confirmed increased levels of collagen I and III 
(but not collagen IV) in soleus muscle of 6-mo-old TWEAK-Tg 
In  recent  years,  remarkable  progress  has  been  made   
toward understanding the intracellular mechanisms responsible 
for loss of skeletal muscle mass in various atrophying condi-
tions. Nuclear factor B (NF-B) is a major proinflammatory 
transcription factor that is strongly linked to skeletal muscle 
wasting not only in chronic diseases but also in disuse condi-
tions (Li et al., 2008). Specific inhibition of NF-B activity 
has been found to rescue muscle atrophy in response to tumor 
growth, denervation, and unloading (Cai et al., 2004; Hunter 
and Kandarian, 2004; Mourkioti et al., 2006). Activation of   
NF-B is sufficient to induce a particular E3 ubiquitin ligase, 
MuRF1 (Cai et al., 2004), which is required for skeletal muscle 
atrophy (Bodine et al., 2001a). MuRF1 activation causes the 
breakdown of myosin heavy chain (MyHC) and other com-
ponents of the thick filament of the sarcomere during atrophy 
(Clarke et al., 2007; Cohen et al., 2009). In addition to MuRF1, 
a second E3 ligase called MAFbx or Atrogin-1 is also induced 
(Bodine et al., 2001a; Gomes et al., 2001), although not via   
NF-B (Cao et al., 2005).
Although the potential role of proinflammatory cytokines 
in muscle-wasting in chronic diseases is now recognized, little 
is known about the triggers and/or the molecular events leading 
to loss of skeletal muscle mass in disuse conditions. In this study, 
we demonstrate that constitutive overexpression of TWEAK 
causes significant muscular abnormalities reminiscent of skele-
tal muscle wasting in chronic diseases. More importantly,   
we demonstrate that TWEAK is also an important mediator of 
skeletal muscle atrophy in response to denervation. Transgenic 
overexpression of TWEAK in skeletal muscle exacerbates atro-
phy, whereas genetic ablation of TWEAK rescues the loss of 
skeletal muscle mass and strength after denervation. Our results 
also show that TWEAK functions through the activation of   
NF-B and by stimulating the expression of the E3 ubiquitin   
ligase MuRF1 in denervated skeletal muscle.
Results
Characterization of TWEAK  
transgenic (TWEAK-Tg) and TWEAK 
knockout (TWEAK-KO) mice
To  examine  the  contribution  of TWEAK  in  skeletal  muscle   
physiology  and  pathophysiology,  transgenic  mice  were  gen-
erated  overexpressing  wild-type  TWEAK  using  the  muscle- 
specific creatine kinase (CK) promoter (Kronqvist et al., 2002). 
Previously, founder TWEAK-Tg mice were produced that ex-
pressed high levels (>14-fold) of TWEAK protein; these mice 
were significantly smaller in size and died at perinatal or neo-
natal stages because of excessive muscle loss (Dogra et al., 
2007a). However, by performing additional pronuclear injec-
tions  of  transgenic  DNA,  we  have  now  established  two  ad-
ditional TWEAK-Tg  lines  (Fig.  1 A).  Because TWEAK-Tg 
mice were generated in B6D2F1 background, these mice were 
crossed with C57BL/6 mice for seven generations before using 
them for this study. Both of the transgenic lines expressed simi-
lar elevated levels of TWEAK in skeletal muscle and showed no 
major variation in any of the phenotypes reported in this study. 
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CSA in soleus muscle of TWEAK-KO mice was 12% higher 
compared with age-matched control mice, demonstrating that 
TWEAK modulates normal muscle size (Fig. 2 B).
Results from previous studies favor the idea that exercise 
intolerance in chronic diseases is attributable to a shift from the 
slow-twitch, fatigue-resistant oxidative fibers to the more fatiga-
ble, fast-twitch glycolytic fibers (Drexler et al., 1992; Pette and 
Staron, 2001). To evaluate the role of TWEAK in skeletal muscle 
fiber–type remodeling, double immunostaining was performed 
on soleus muscle sections using antibody against laminin and an 
antibody that recognizes all three fast-type fibers, IIa, IIx, and 
IIb. Compared with controls (48.3 ± 1.3%), the number of fast-
type fibers was increased in TWEAK-Tg (63.6 ± 3.6%) and re-
duced in TWEAK-KO (42.8 ± 1.2%) mice (Fig. 2, C and D), 
suggesting that TWEAK favors a transition from slow- to fast-
type fibers. To further confirm the role of TWEAK in fiber-type 
switching, we also performed immunostaining on extensor   
digitorum longus (EDL) muscle sections using an antibody that 
recognizes only type I fibers along with laminin antibody.   
mice compared with control mice (Fig. S1, A and B). However, 
we did not find any significant difference in the protein level of 
TGF-, which is a predominant mediator of the development 
of interstitial fibrosis in skeletal muscle, between control and 
TWEAK-Tg (Fig. S1 B). To evaluate whether increased fibrosis 
in soleus muscle of TWEAK-Tg mice was caused by increased 
infiltration of immune cells, especially macrophages, we studied 
the levels of macrophages in skeletal muscle tissues. However, 
there was no difference in the number of macrophages in soleus 
muscle of control, TWEAK-Tg, and TWEAK-KO mice, which 
was also confirmed by measuring transcript levels of CD68 
and Mac-1, which are the major cell surface markers for macro-
phages, by QRT-PCR (Fig. S2). In contrast to TWEAK-Tg mice,   
TWEAK-KO mice showed normal soleus muscle structure and 
no indication of fibrosis (Fig. 2 A). The changes in fiber size   
were  quantified  after  immunostaining  soleus  muscle  sec-
tions (Fig. 2 A, bottom) for laminin and measuring fiber CSA.   
The mean fiber CSA of soleus muscle was reduced by 33% 
in 6-mo-old TWEAK-Tg mice. Furthermore, the mean fiber 
Figure 1.  Characterization of TWEAK-Tg and TWEAK-KO mice. (A) Fold change in mRNA levels of TWEAK in skeletal muscle and other organs of 
TWEAK-Tg mice (n = 6) compared with littermate control (n = 6) mice. (B) Fold change in protein levels of TWEAK in skeletal muscle, other organs, and 
serum of TWEAK-Tg (n = 3) mice compared with control (n = 3) mice. (A and B) *, P < 0.01 (values significantly different from littermate control mice).   
(C) Fold change in the mRNA levels of TWEAK receptor Fn14 in TA muscle of TWEAK-Tg (n = 5) and TWEAK-KO (n = 6) mice compared with control   
(n = 6) mice. *, P < 0.01 (values significantly different from age-matched wild-type mice). (D) Fold change in mRNA levels of TNF, IL-1, and IL-6 in TA 
muscle of TWEAK-Tg (n = 3) mice compared with control mice (n = 3). (E) Serum CK levels in TWEAK-Tg or TWEAK-KO mice compared with control mice 
measured using a CK assay kit (Stanbio Laboratory). (A–E) Error bars represent the SD. Dashed lines represent the basal levels in control mice.JCB • VOLUME 188 • NUMBER 6 • 2010   836
Figure 2.  Effect of TWEAK on skeletal muscle phenotypes in vivo. (A) Soleus muscle from 6-mo-old control (n = 6), TWEAK-Tg (n = 8), and TWEAK-KO   
(n = 5) mice was analyzed after H&E or Masson’s trichrome staining or after immunostaining with laminin antibody. (B) Quantification of mean fiber CSA 
in soleus muscle of control, TWEAK-Tg, and TWEAK-KO mice. *, P < 0.01; and 
#, P < 0.05 (value significantly different from control mice). (C) Representa-
tive photomicrographs of soleus muscle sections from 6-mo-old control (n = 6), TWEAK-Tg (n = 7), and TWEAK-KO (n = 6) mice taken after immunostain-
ing with anti–MyHC fast type and antilaminin. (D) Quantification of MyHC fast type–positive (filled with green color in C) and -negative fibers (empty) in 837 TWEAK regulates denervation-induced muscle atrophy • Mittal et al.
to determine whether the TWEAK–Fn14 pathway perturbed 
physiological atrophy. To address this issue, first, it was investi-
gated whether the expression of TWEAK or its receptor Fn14 is   
affected in skeletal muscle in conditions of atrophy and hyper-
trophy in vivo, as determined by Affymetrix microarray analy-
sis. To induce atrophy, 12-wk-old mice were treated with a cast 
on a lower limb for 3–7 d or denervated for 3–7 d (meaning the 
sciatic nerve was transected), as previously described (Bodine 
et al., 2001a). To study hypertrophy, the casted muscles were 
allowed to recover for 1 wk after the casts were removed. Also, 
as an additional model of hypertrophy, animals were treated 
with clenbuterol for 1 wk, as described previously (Hinkle et al., 
2002). Although TWEAK expression did not change signifi-
cantly either in settings of atrophy or hypertrophy (not depicted), 
the  expression  of  TWEAK  receptor  Fn14  was  found  to  be   
up-regulated upon casting or denervation (Fig. 4 A). Fn14 was 
not universally up-regulated in atrophy conditions because the 
glucocorticoid dexamethasone did not cause its up-regulation 
(Fig. 4 A). In contrast, the expression of Fn14 was found to be 
somewhat reduced in conditions of hypertrophy such as clen-
buterol and casting recovery (Fig. 4 A).
We also measured the expression of Fn14 in denervated 
skeletal muscle using real-time PCR and Western blot methods. 
Once again, it was observed that the mRNA level of Fn14 but 
not TWEAK was increased approximately six- to sevenfold in 
denervated gastrocnemius (GA) muscle compared with contra-
lateral sham-operated control muscle (Fig. 4 B). To determine 
whether  denervation-induced  elevation  in  mRNA  level  was 
specific to the TWEAK receptor Fn14, in the same experiment, 
we also measured the levels of TNF receptors 1 and 2 (TNFR1 
and -2; Fig. 4 B), which belong to the same TNF receptor   
super  family  of  which  Fn14  is  also  a  member  (Winkles, 
2008). However, no significant increase in the mRNA levels   
of TNFR1 or -2 was observed between denervated and sham-
operated control GA muscle (Fig. 4 B). Similar to mRNA, the 
protein level of Fn14 in GA muscle was also drastically increased, 
and it remained elevated even after 10 d of denervation, sug-
gesting a potential role of the TWEAK–Fn14 pathway in skele-
tal muscle atrophy (Fig. 4 C). Furthermore, we observed that 
the expression of Fn14 was equally increased in soleus (slow/
mixed) and GA, TA, and EDL muscles (fast type) upon dener-
vation (Fig. 4, D and E).
Denervation-induced skeletal muscle 
atrophy is rescued in TWEAK-KO mice
We next determined whether the loss of skeletal muscle mass in   
response to denervation is modulated in TWEAK-Tg or TWEAK-
KO mice. Because at 3 mo TWEAK-Tg or TWEAK-KO mice did   
not show any apparent skeletal muscle phenotype and  mice 
at this age are fully developed, we used 3-mo-old mice to 
evaluate  the  role  of  TWEAK  in  denervation-induced  loss 
Again, the number of slow-type fibers was found to be signifi-
cantly reduced in TWEAK-Tg mice and increased in TWEAK-KO 
mice as compared with control mice (Fig. 2, E and F). Compari-
son of CSA of slow- and fast-type fibers in soleus muscle of 
control and TWEAK-Tg mice revealed an 36% reduction in 
fast-type fibers and only an 7.2% reduction in slow-type fibers, 
suggesting that TWEAK-induced atrophy is predominantly 
restricted to fast-type fibers (Fig. 2 G).
TWEAK triggers activation of proteolytic 
pathways in vivo
What is the mechanism of action by which TWEAK induces skel-
etal muscle atrophy in vivo? It was of interest to know whether 
TWEAK induces atrophy by perturbing protein synthesis or 
proteolysis and if the latter was activated, whether particular 
proteins were subjected to degradation in a TWEAK-dependent   
manner. A marked reduction in the levels of MyHC, tropo-
myosin, and neuronal nitric oxide synthase (nNOS) was ob-
served  in  the  soleus  muscle  of  TWEAK-Tg  mice,  whereas 
TWEAK-KO mice showed an increase in the levels of both 
MyHC  and  nNOS  proteins  compared  with  control  mice   
(Fig. 3, A–C). The levels of cytoplasmic proteins troponin and 
sarcomeric -actin and cytoskeletal proteins dystrophin and 
laminin showed no noticeable changes (Fig. 3, A and B).
QRT-PCR analysis revealed no significant changes in mRNA 
levels of MyHC or nNOS in soleus muscle of TWEAK-Tg and 
TWEAK-KO  mice  compared  with  control  mice  (Fig.  3  D), 
suggesting that the reduction in the levels of proteins in the 
TWEAK-Tg  mice  was  not  the  result  of  reduced  transcrip-
tion but rather was a result of a perturbation in protein levels.   
An  increase  in  proteolysis  was  suggested  downstream  of 
TWEAK activation by the observation that the activation of 
NF-B (but not activator protein AP-1) and level of MuRF1, 
a  muscle-specific  E3  ligase  which  is  required  for  muscle   
atrophy  (Bodine  et  al.,  2001a),  were  significantly  higher   
(1.6  ±  0.2–fold;  P  <  0.05)  in  soleus  muscle  of  6-mo-old 
TWEAK-Tg mice compared with control mice (Fig. 3, E and F). 
In contrast, there was no significant difference in the mRNA 
levels  of  MAFbx  (another  muscle-specific  E3  ligase)  be-
tween  control  and  TWEAK-Tg  mice  (Fig.  3  F).  It  was   
recently shown that MuRF1 is the NF-B–regulated E3 ligase 
for MyHC (Cai et al., 2004; Clarke et al., 2007); therefore, 
the coincident demonstration of a TWEAK-induced increase 
in NF-B and MuRF1 and a decrease in MyHC suggests that 
TWEAK promotes atrophy by inducing the degradation of 
specific muscle proteins in vivo.
Expression of TWEAK receptor Fn14 is 
increased in denervated skeletal muscle
Although it was of interest to learn that increased TWEAK   
levels were sufficient to induce muscle atrophy, it was important 
control, TWEAK-Tg, and TWEAK-KO mice. (E) Representative photomicrographs of EDL muscle sections from 6-mo-old control (n = 4), TWEAK-Tg (n = 4),   
and TWEAK-KO (n = 4) mice taken after immunostaining with anti–type I and antilaminin. (F) Percentage of type I fibers (filled with red color in E) in 
control, TWEAK-Tg, and TWEAK-KO mice. (D and F) */
#, P < 0.05 (values significantly different from control mice). (G) Measurement of mean fiber 
CSA of fast- and slow-type fibers in control (n = 5) and TWEAK-Tg (n = 5) mice. *, P < 0.01 (value significantly different from slow-type fibers). (B, D,   
F, and G) Error bars represent the SD. Bars, 50 µm.
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with H&E dyes (Fig. 5 C) and found that the mean fiber CSA 
in TA muscle was significantly reduced in TWEAK-Tg mice 
compared with control mice after denervation (Fig. 5 D). In 
contrast, the fiber CSA was significantly preserved in skeletal 
muscle of TWEAK-KO mice after denervation (Fig. 5, C and D). 
Similar results were obtained with soleus (Fig. 5, E and F) and 
GA and EDL muscles (not depicted).
Fibrosis is an important pathological feature in various 
muscular disorders and is observed in paraplegic patients, who 
of skeletal muscle mass. Gross analysis showed that the loss   
of GA muscle was increased in TWEAK-Tg mice and rescued   
in TWEAK-KO mice compared with control mice 10 d after 
denervation (Fig. 5 A). Indeed, the measurement of individual   
muscle  weight  confirmed  that  transgenic  overexpression  of 
TWEAK  stimulates  denervation-induced  loss  of  skeletal   
muscle mass (Fig. 5 B). Conversely, TWEAK-KO mice showed 
reduced loss of skeletal muscle mass upon denervation (Fig. 5 B). 
We also assessed the fiber CSA after staining muscle sections 
Figure 3.  Effect of TWEAK on the expression of specific muscle proteins in vivo. (A) Representative Western blots for MyHC, nNOS, tropomyosin, 
troponin, sarcomeric -actin, dystrophin, laminin, and tubulin in soleus muscle of 6-mo-old control and TWEAK-Tg mice. (B) Representative Western 
blots for various muscle proteins in soleus muscle of 6-mo-old control and TWEAK-KO mice. (A and B) Black lines indicate that intervening lanes have been 
spliced out. (C) Fold change in protein levels of MyHC and nNOS in soleus muscle of control (n = 6), TWEAK-Tg (n = 5), and TWEAK-KO (n = 6) mice.   
*/
#, P < 0.05 (values significantly different from control mice). (D) Fold change in mRNA levels of MyHC and nNOS in soleus muscle of control (n = 6), TWEAK-Tg   
(n = 5), and TWEAK-KO (n = 4) mice. (E) Activation of NF-B but not AP-1 transcription factor in soleus muscle of 6-mo-old TWEAK-Tg compared with 
littermate control mice. (F) Fold difference in mRNA levels of MAFbx and MuRF1 in control and TWEAK-Tg mice. *, P < 0.01 (values significantly different 
from level of MuRF1 in control mice). (C, D, and F) Error bars represent the SD. Dashed lines represent the basal levels in control mice.839 TWEAK regulates denervation-induced muscle atrophy • Mittal et al.
Because ablation of TWEAK attenuated muscle atrophy 
upon denervation, we next determined whether the absence 
of TWEAK also affects muscle force production in isometric 
contractions in denervated skeletal muscle. We noted a signi-
ficant decrease in soleus muscle absolute force production 
after denervation in control mice, which was significantly 
preserved in TWEAK-KO mice (Fig. 6 C). These results fur-
ther support the inference that blocking TWEAK represents 
a promising strategy to counteracting skeletal muscle atro-
phy elicited by denervation.
Pharmacological inhibition of TWEAK 
attenuates denervation-induced skeletal 
muscle atrophy in mice
We also investigated whether blockade of TWEAK activity 
using a rat anti–mouse TWEAK-neutralizing antibody (Nakayama 
et al., 2003; Kamata et al., 2006) can prevent the denervation-
induced skeletal muscle loss in mice. Interestingly, treatment 
suffer from permanent denervation. Because proinflammatory 
cytokines have been traditionally suggested as one of the most 
important  mediators  of  fibrosis  in  chronic  diseases  (Drexler   
et al., 1992) and TWEAK-Tg mice showed increased fibrosis at 
the age of 6 mo (Fig. 2 A, middle), we next investigated whether 
overexpression or genetic ablation of TWEAK in mice affects 
the extent of fibrosis in skeletal muscle in response to denerva-
tion. Staining of muscle sections with Sirius red dye, which   
labels collagen fibers (Lahoute et al., 2008), showed a drastic in-
crease in the accumulation of collagen fibers in denervated TA 
muscle of TWEAK-Tg mice compared with controls. Further-
more, the level of fibrosis was somewhat reduced in denervated 
TA muscle of TWEAK-KO mice after 21 d of denervation   
(Fig. 6 A). Increased fibrosis in TWEAK-Tg and its reduction in 
TWEAK-KO mice compared with control mice upon denerva-
tion was also confirmed by measuring the mRNA levels of colla-
gen I (i.e., Col1a2, major collagen in skeletal muscle) in TA and 
soleus muscles by the QRT-PCR technique (Fig. 6 B).
Figure 4.  Expression of TWEAK and Fn14 in skeletal muscle upon denervation. (A) Expression of Fn14 in skeletal muscle in response to casting (Cast.), 
denervation (Den.), and dexamethasone (Dex.) treatment to induce atrophy and in response to clenbuterol (Clen.) and recovery (Recov.) from casting 
to induce hypertrophy. Animals were also studied under free-running exercise conditions (exercise). mRNA was taken at the time points indicated and   
assessed in an Affymetrix microarray study. mRNA from 10 animals (n = 10) were used for each condition. (B) Relative mRNA levels of TWEAK, Fn14, 
and TNFR1 and -2 in denervated GA muscle versus sham-operated contralateral GA muscle after 4 d from 12-wk-old C57BL/6 mice (n = 5). *, P < 0.01.   
(A and B) Error bars represent the SD. Dashed lines represent the basal levels in control mice. (C) Levels of Fn14 protein measured by Western blotting in 
control (C) and denervated (D) GA muscle of C57BL/6 mice at 4, 7, or 10 d of denervation. (D) Expression of Fn14 protein in GA, TA, soleus, and EDL 
muscle of mice measured 4 d after denervation. The black line indicates that intervening lanes have been spliced out. (E) Representative Western blots 
showing expression of slow-type (st) MyHC (using clone A4.840) and fast-type (ft) MyHC (using clone BF-F3) in GA, TA, soleus, and EDL muscle of mice.JCB • VOLUME 188 • NUMBER 6 • 2010   840
TWEAK is an upstream activator of NF-B 
in denervated skeletal muscle
NF-B is a transcription factor that causes skeletal muscle   
wasting and is activated by cytokines (Cai et al., 2004; Mourkioti   
et al., 2006). To understand the intracellular signaling mechanisms   
of mice with MTW1 antibody significantly increased the fiber 
CSA in denervated TA and soleus muscle of MTW1-treated 
mice compared with isotype control-treated mice (Fig. 7), 
further suggesting that TWEAK is a mediator of denervation-
induced skeletal muscle atrophy.
Figure 5.  Role of TWEAK in denervation-induced skeletal muscle atrophy. (A) 3-mo-old control, TWEAK-Tg, and TWEAK-KO mice 10 d after denervation 
procedure. Arrows point to denervated GA muscle. (B) TA and soleus muscle were isolated from tendon to tendon from control, TWEAK-Tg, and TWEAK-KO 
mice 10 d after denervation (n = 6 per group), and their wet weight was measured. */
#, P < 0.05 (values significantly different from corresponding muscle 
of control mice). (C) H&E-stained sections of TA of control, TWEAK-Tg, and TWEAK-KO mice 10 d after denervation. (D) Quantification of fiber CSA of TA 
muscle in control, TWEAK-Tg, and TWEAK-KO mice 10 d after denervation (n = 8 in each group). (E) Representative photomicrographs of H&E-stained 
soleus muscle sections from control, TWEAK-Tg, and TWEAK-KO mice 12 d after denervation. (F) Measurement of fiber CSA in H&E-stained soleus muscle 
sections in control, TWEAK-Tg, and TWEAK-KO mice 12 d after denervation (n = 6 in each group). (D and F) *, P < 0.01; and 
#, P < 0.05 (values signifi-
cantly different from that of control mice at indicated time after denervation). (B, D, and F) Error bars represent the SD. Bars, 20 µm.841 TWEAK regulates denervation-induced muscle atrophy • Mittal et al.
by which TWEAK–Fn14 stimulates the loss of skeletal muscle   
mass in response to denervation, we measured the activation   
of  NF-B  in  control  and  denervated  skeletal  muscle  of 
TWEAK-Tg  and  TWEAK-KO  mice.  DNA-binding  activity 
of  NF-B,  measured  by  electrophoretic  mobility  shift  assay 
(EMSA), was found to be significantly increased in dener-
vated muscle of TWEAK-Tg mice as compared with control 
mice (Fig. 8 A). In contrast, the denervation-induced activa-
tion of NF-B was significantly reduced in TWEAK-KO mice   
(Fig. 8 B). To confirm that the retarded bands seen in EMSA 
were indeed NF-B, we performed a supershift assay. Preincu-
bation of nuclear extracts from denervated GA muscle of con-
trol mice with antibodies against p50 or p52 shifted the bands   
to higher levels of molecular weight, indicating that the NF-B–
DNA complex analyzed by EMSA constitutes these proteins 
(Fig. 8 C). Furthermore, by electroporating TA muscle with 
NF-B reporter plasmid, we also confirmed that the observed 
changes in the DNA-binding activity of NF-B in denervated 
skeletal muscle of control, TWEAK-Tg, and TWEAK-KO mice 
were  highly  correlated  with  the  transcriptional  activation  of   
NF-B (Fig. 8 D).
Besides NF-B, the PI3K–Akt signaling pathway is also 
an important regulator of skeletal muscle mass in vivo (Glass, 
2003). Activation of Akt augments skeletal muscle mass in vivo 
by  stimulating  anabolic  and  suppressing  catabolic  pathways 
(Bodine et al., 2001b; Lai et al., 2004; Blaauw et al., 2008). It 
has been reported that denervation causes suppression of Akt 
activity in skeletal muscle, whereas constitutive activation of 
Akt blunts the loss of skeletal muscle mass upon denervation 
(Bodine et al., 2001b; Stitt et al., 2004; Mourkioti et al., 2006). 
Our results showed that although levels of phosphorylated   
Akt, mammalian target of rapamycin (mTOR), p70S6K, and 
GSK3- were reduced in GA muscle 10 d after denervation, 
there was no noticeable difference in the levels of phosphory-
lated Akt, mTOR, GSK3-, or p70S6K between denervated mus-
cle of control, TWEAK-Tg, and TWEAK-KO mice (Fig. S3).
TWEAK acts through up-regulation of the 
ubiquitin–proteasome system
The amount of ubiquitin protein conjugates and the expres-
sion of the components of ubiquitin degradation pathways 
are significantly enhanced during atrophy (Attaix and Bechet, 
2007). In genetic screens for the markers of muscle atrophy, 
two genes, MAFbx (also known as Atrogin-1) and MuRF1, 
both encoding ubiquitin ligases, were identified that are highly   
induced in vivo in atrophying muscle, driven by immobili-
zation, denervation, hind limb suspension, starvation, tumor 
Figure 6.  Role of TWEAK in development of fibrosis and loss of muscle 
function. (A) Sirius red staining performed on TA muscle sections after 21 d   
of denervation in control, TWEAK-Tg, and TWEAK-KO mice (n = 4 in each   
group). (B) Fold change in the mRNA levels of collagen type 1,  2 (Col1a2)   
in  TA  and  soleus  muscle  of  control  (n  =  6),  TWEAK-Tg  (n  =  3),  and 
TWEAK-KO (n = 3) mice 10 d after denervation measured by QRT-PCR.   
*/
#, P < 0.01 (values significantly different from denervated muscle of 
control mice). (C) Denervation-induced loss in absolute muscle force pro-
duction in isometric contraction was measured in soleus muscle of control 
(n = 5) and TWEAK-KO (n = 6) mice at 80, 120, 150, 220, and 300 Hz.   
*, P < 0.01 (values significantly different from the denervated soleus mus-
cle of control mice at same frequency). (B and C) Error bars represent the 
SD. Bars, 50 µm.
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regulated by NF-B activation (Cai et al., 2004). In contrast, 
there was no significant difference in the level of MAFbx ex-
pression between denervated muscle of control, TWEAK-Tg, 
and TWEAK-KO mice (Fig. 9 B), which is again consistent 
with a prior study showing that activation of NF-B induced 
MuRF1 but not MAFbx expression (Cai et al., 2004). Further-
more, by performing Western blot analysis, we found that the 
protein level of MuRF1 was also elevated in TWEAK-Tg and 
reduced in TWEAK-KO mice compared with control mice in 
denervated muscles (Fig. 9 C).
It should be noted that in the naive, undenervated, trans-
genic animals, NF-B (Fig. 8 A) or MuRF1 (Fig. 9 B) was not up-
regulated. This is because these experiments were performed 
load, and glucocorticoids (Bodine et al., 2001a; Gomes et al., 
2001; Glass, 2005). The role of MAFbx and MuRF1 has been 
confirmed by the findings that the loss-of-function mutations   
in either of these genes reduced skeletal muscle atrophy in 
response  to  divergent  catabolic  stimuli,  including  denerva-
tion (Bodine et al., 2001a). We studied the expression patterns 
of MAFbx and MuRF1 by QRT-PCR in the transgenic and 
knockout animals versus controls. The expressions of both 
MAFbx and MuRF1 were significantly increased in denervated 
GA muscle compared with sham-operated control muscle (Fig. 9,   
A and B). The mRNA levels of MuRF1 were significantly in-
creased in TWEAK-Tg and significantly decreased in TWEAK- 
KO mice (Fig. 9 A), which is consistent with MuRF1 being   
Figure 7.  TWEAK-neutralizing antibody rescues denervation-induced muscle loss in mice. 2-mo-old C57BL/6 mice were denervated for 2 d, followed 
by intraperitoneal injections of 200 µg/mouse of either rat IgG1 or anti-TWEAK every third day for 12 d (n = 4 in each group). (A) Representative photo-
micrographs of H&E-stained sections of control and denervated TA muscle of isotype and anti-TWEAK–treated mice. (B) Quantification of fiber CSA in 
TA muscle sections of isotype and anti-TWEAK–treated mice. *, P < 0.01 (values significantly different from denervated TA muscle of IgG1-treated mice).   
(C) H&E-stained sections of control and denervated soleus muscle of mice treated with isotype or anti-TWEAK. (D) Quantification of fiber CSA in soleus 
muscle sections. 
#, P < 0.05 (values significantly different from denervated soleus muscle of IgG1-treated mice). (B and D) Error bars represent the SD.   
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Atg-5, Atg-12, and Gabarapl1 in denervated muscle of control, 
TWEAK-Tg, and TWEAK-KO mice. Although a significant in-
crease in mRNA levels of all of the five genes was observed in 
denervated skeletal muscle, there was no significant difference 
in the mRNA levels of any of these genes in denervated muscle 
of TWEAK-Tg or TWEAK-KO mice compared with control 
mice (Fig. S4).
Discussion
Skeletal muscle atrophy is commonly observed in disuse condi-
tions such as denervation, unloading, and immobilization (Späte 
and Schulze, 2004; Glass, 2005; Sandri, 2008). Proinflamma-
tory cytokines have been suggested both to induce and mediate 
on 3-mo-old animals, before a phenotype is seen in the trans-
genics. By 6 mo of age, atrophy, fibrosis, and NF-B and 
MuRF1  up-regulation  were  noted  in  unperturbed  animals 
(Figs. 2 and 3).
Recent evidence also suggests that lysosomal proteolysis 
may also contribute to the loss of muscle protein during atrophy 
(Mammucari et al., 2007; Zhao et al., 2007, 2008). Autophago-
some formation has been demonstrated in skeletal muscle of 
mice in response to fasting or denervation (Mordier et al., 2000; 
Mammucari et al., 2007). The expression of several genes   
involved in the autophagy pathway has been found to be in-
creased in denervated skeletal muscle (Zhao et al., 2007). To 
understand whether TWEAK affects autophagy, we compared 
mRNA levels of autophagy-related molecules LC3B, Beclin-1, 
Figure 8.  Role of TWEAK in the activation of NF-B in denervated skeletal muscles. DNA-binding activity of NF-B was measured by EMSA in TA muscle 
10 d after denervation. (A and B) Representative EMSA gel from three independent experiments for control and TWEAK-Tg mice (A) and control and 
TWEAK-KO mice (B). (C) Supershift assay performed using nuclear extracts from denervated GA muscle of control mice using antibodies against p50 
and p52 subunits of NF-B. (D) Fold change in NF-B reporter gene activity (normalized using Renilla luciferase) in TA muscle of control, TWEAK-Tg,   
and TWEAK-KO mice after denervation. *, P < 0.01; and 
#, P < 0.05 (values significantly different from corresponding control mice). Error bars represent 
the SD. U, undenervated; D, denervated; PIS, preimmune serum.JCB • VOLUME 188 • NUMBER 6 • 2010   844
Transgenic mice overexpressing TWEAK four- to six-
fold show no gross phenotype until the animals are around 6 mo   
of age. At that time, a decrease in muscle fiber size can be 
observed, which is coincident with an increase in fibrosis, 
which is a similar phenotype to that seen in settings of dener-
vation (Figs. 2 A and 6, A and B). Coincident with the onset 
of atrophy, there is an increase in the activity of NF-B tran-
scription factor (Fig. 3 E) and the levels of the E3 ubiquitin 
ligase MuRF1 (Fig. 3 F) but not those of a second muscle-
specific E3 ligase, MAFbx (Bodine et al., 2001a). MuRF1 
and MAFbx are found to be coactivated in many settings of 
muscle atrophy (Bodine et al., 2001a; Gomes et al., 2001). 
However, it was also previously demonstrated that discrete 
activation of the NF-B pathway induces MuRF1 but not 
MAFbx expression, placing MuRF1 downstream of NF-B 
(Cai et al., 2004; Glass, 2005); MAFbx can be activated by 
p38 signaling (Li et al., 2005).
MuRF1 is a specific E3 ligase for MyHC protein (Clarke 
et al., 2007; Fielitz et al., 2007). It degrades MyHC and other 
local  catabolic  mechanisms  at  advance  stages  of  chronic   
diseases,  leading  to  cachexia  (Späte  and  Schulze,  2004;   
Argilés et al., 2005; Li et al., 2008); however, because disuse-
related skeletal muscle atrophy does not involve any systematic   
inflammatory response, the involvement of proinflamma-
tory cytokines in this type of atrophy has received limited   
attention. The results of this study provide strong evidence, 
for the first time, that the inflammatory cytokine TWEAK   
is  an  important  mediator  of  denervation-induced  skeletal   
muscle atrophy.
Overexpression of TWEAK is sufficient to 
cause skeletal muscle atrophy in vivo
New transgenic mice were produced, in which TWEAK was 
overexpressed four- to fivefold (Fig. 2, A and B). These animals 
live into adulthood, in contrast to prior TWEAK transgenics, in 
which the cytokine was expressed at 14-fold normal levels; those 
animals died peri- or neonatally because of excessive muscle 
loss (Dogra et al., 2007a).
Figure 9.  Effects of TWEAK on the expression 
of muscle-specific E3 ubiquitin ligases in de-
nervated skeletal muscle. (A) Relative mRNA 
levels of MAFbx in denervated GA muscle of 
TWEAK-Tg or TWEAK-KO versus control mice 
(n = 6 in each group). */
#, P < 0.01 (values 
significantly different from corresponding con-
trol mice). (B) Relative mRNA levels of MuRF1 
in  denervated  GA  muscle  of  TWEAK-Tg  or 
TWEAK-KO  versus  control  mice  (n  =  6  per 
group). (A and B) Error bars represent the SD. 
(C) Representative immunoblots demonstrating 
MuRF1 protein levels in undenervated (U) and 
denervated (D) GA muscle of control, TWEAK-Tg,   
and TWEAK-KO mice. Black lines indicate that 
intervening lanes have been spliced out.845 TWEAK regulates denervation-induced muscle atrophy • Mittal et al.
required for skeletal muscle strength in vivo (Percival et al., 
2008). Our results indicate that the increased levels of TWEAK 
may destabilize the sarcolemma in part by reducing the level of 
nNOS, thus disturbing the equilibrium and resulting in atrophy, 
and by up-regulating NF-B–MuRF1 signaling, causing actual 
breakdown of the thick filament.
Genetic ablation of TWEAK spares skeletal 
muscle under denervation conditions
Our previous study showed that the expression of the receptor 
Fn14 but not TWEAK itself might be important for the cata-
bolic action of TWEAK in skeletal muscle in vivo (Dogra et al., 
2007a). Although the expression of TWEAK in skeletal muscle 
does not change, the levels of Fn14 are significantly reduced   
after initial stages of development (Dogra et al., 2007a). Other re-
ports also suggest that Fn14 is expressed at relatively low level 
in normal tissues (Tanabe et al., 2003; Winkles, 2008). However, 
the expression of Fn14 is highly up-regulated in response to tis-
sue injury, regeneration, and in chronic inflammatory diseases, 
supporting its role in tissue remodeling (Tanabe et al., 2003; 
Winkles, 2008). Although the underpinning mechanisms lead-
ing to the increased expression of Fn14 remain unknown, this 
study demonstrates that the activation of the TWEAK–Fn14 
pathway mediates the loss of skeletal muscle mass and strength 
upon denervation (Figs. 5, 6 C, and 7). Additionally, increased 
fibrosis in the denervated muscle of the TWEAK-Tg mice fur-
ther supports the contention that TWEAK is a major regulator 
of fibrosis in atrophying conditions (Fig. 6, A and B).
The loss of skeletal muscle proteins in atrophying muscle   
is mediated by the activation of the ATP-dependent ubiquitin– 
proteasome pathway, with an associated increase in the expres-
sion of the E3 ubiquitin ligases MAFbx and MuRF1 (Glass, 
2003, 2005). Before this study, the identity of particular upstream   
triggers of atrophy in the various models remained unknown.   
The  results  presented  in  this  study  demonstrate  that  the   
activation  of  the  TWEAK–Fn14  system  specifically  activates   
NF-B in denervated muscle (Fig. 8). Although skeletal muscle 
wasting might involve coordinated activation of multiple cell 
signaling pathways, NF-B activation in skeletal muscle is suf-
ficient to cause skeletal muscle wasting (Cai et al., 2004; Li 
et al., 2008), in part by activating MuRF1, because muscle-
wasting  in  IKK-–overexpressing  transgenic  mice  was  sig-
nificantly reduced by crossing them with MuRF1-KO mice   
(Cai et al., 2004). Furthermore, skeletal muscle–specific dele-
tion of IKK- in mice reduces the expression of MuRF1 and 
atrophy in response to denervation (Mourkioti et al., 2006).   
Although  MAFbx  was  activated  by  denervation  in  these   
experiments (Fig. 9), which is in line with prior studies (Bodine   
et al., 2001a; Gomes et al., 2001), this E3 ligase was not further   
perturbed  by  the  addition  or  deletion  of  TWEAK,  adding   
further evidence to the published report that NF-B activation 
does not up-regulate MAFbx expression (Cai et al., 2004).
It is also of interest to note some of the pathways that 
TWEAK  did  not  activate. Although  TWEAK  was  found  to 
stimulate the NF-B pathway, it did not affect the activation of 
Akt (Fig. S3) or autophagy pathway (Fig. S4) in denervated 
skeletal  muscle.  Collectively,  our  results  suggest  that  the 
components of the thick filament such as myosin light chain 
(Cohen  et  al.,  2009). The  loss  of  MyHC  in  the  6-mo-old 
TWEAK-Tg animals (Fig. 3 A) indicates that the MuRF1–
MyHC pathway has been activated by TWEAK–Fn14 signal-
ing, establishing a TWEAK–Fn14–NF-B–MuRF1–MyHC 
protein degradation cascade.
It is of interest that otherwise-unperturbed TWEAK-Tg 
animals did not display a phenotype until they were older. This 
suggests the possibility that a second, age-dependent event has 
to occur in order for TWEAK overexpression to be sufficient to 
induce atrophy. The late appearance of the atrophic phenotype 
in TWEAK-Tg mice (i.e., around 4–5 mo) suggests that the   
catabolic action of TWEAK in skeletal muscle may be neutral-
ized by active muscle formation and/or the presence of growth 
factors at a younger age. It is also possible that TWEAK has 
different roles in the acquisition and the maintenance of skeletal 
muscle mass in vivo. It has been previously reported that   
genetic ablation of TWEAK receptor delays the regeneration   
of myofibers in mice (Girgenrath et al., 2006), suggesting that 
TWEAK may also be essential for the proliferation of muscle 
progenitor cells during skeletal muscle growth. Furthermore, we 
found that increased concentration of TWEAK induces fibrosis 
in skeletal muscle (Fig. 2 A). These data are consistent with a 
recent study demonstrating that increased levels of TWEAK   
in circulation induce fibrosis in cardiac muscle (Jain et al., 
2009). The increased number of type II fibers in soleus muscle 
of TWEAK-Tg mice also indicates that the elevated levels   
of TWEAK are sufficient to induce transition of slow-type   
fibers into fast-type fibers and its absence increases the propor-
tion of slow-type fibers (Fig. 3, C–F).
Although it is of interest to show that ectopic, enhanced 
expression of TWEAK is sufficient to induce skeletal muscle 
atrophy, that finding by itself does not explain what happens 
under normal settings of atrophy. Therefore, it was interesting 
to see that genetic ablation of TWEAK augments fiber CSA; 
this finding establishes that TWEAK is a negative regulator of 
skeletal muscle mass in adult animals (Fig. 2, A and B).
Recent evidence suggests that muscle wasting in response 
to cancer cachexia involves the degradation of only selective 
muscle proteins (Acharyya et al., 2004, 2005; Acharyya and 
Guttridge, 2007). Cancer cachexia also leads to sarcolemmal 
abnormalities, including the reduced expressions of compo-
nents of the dystrophin–glycoprotein complex in skeletal mus-
cle (Acharyya et al., 2005). Our results demonstrate that skeletal 
muscle atrophy in TWEAK-Tg mice is associated with the   
reduced levels of contractile proteins MyHC and tropomyosin 
(Fig. 3, A and C). Furthermore, the level of nNOS, a protein 
which interacts with the dystrophin–glycoprotein complex in 
skeletal muscle, but not dystrophin and laminin is reduced in 
TWEAK-Tg mice (Fig. 3 A). nNOS dysregulation has been 
shown to be itself sufficient to induce muscle atrophy (Suzuki   
et al., 2007), and recent evidence suggests that the localization 
of nNOS to the sarcolemma is essential for the maintenance of 
normal muscle activity (Kobayashi et al., 2008). Furthermore, 
genetic ablation of nNOS in mice causes significant reduction 
in maximum tetanic force production and increased susceptibil-
ity to contraction-induced fatigue, suggesting that nNOS is   JCB • VOLUME 188 • NUMBER 6 • 2010   846
intraperitoneal injection of 100 mg/kg ketamine and 20 mg/kg xylazine, 
shaving the right hind quarters, making a 0.5-cm incision 0.5 cm proxi-
mal to the knee on the lateral side of the right leg, separating the muscles 
and lifting out the sciatic nerve with a surgical hook or forceps, remov-
ing  a  2–3-mm  piece  of  sciatic  nerve,  and  closing  the  incision  with   
surgical staples.
For casting, mice were anesthetized, and immobilized at the knee 
and ankle joints, with the ankle in plantar flexion to maximize atrophy in 
the posterior compartment muscles. The Plaster of Paris cast encompassed 
one hind limb. For recovery, after 2 wk of atrophy, the cast was removed, 
and the animals were allowed to ambulate freely in their cages. For clen-
buterol treatment, the mice received either physiological saline at 1 ml/kg 
per day or 3 mg/kg per day clenbuterol (Sigma-Aldrich) dissolved in   
water via a subcutaneous injection. 9 d after the denervation surgery, 
mice were anesthetized with isoflurane and euthanized by CO2 asphyxia-
tion. The left and right legs were shaved, the skin on each leg was resected, 
and the TA, soleus, and medial GA muscles were isolated, removed, and 
weighed. All animal procedures were approved by the Institutional Animal 
Care and Use Committee and conformed to the American Physiological 
Society’s Guiding Principles in the Care and Use of Animals. For microar-
rays, Affymetrix mouse 430 version 2 microarrays were used to measure 
gene expression values. Normalization in our analysis was performed   
using the GeneChip robust multiarray averaging normalization method 
(Irizarry et al., 2006).
To study the effects of TWEAK-neutralizing antibody (Clone MTW1; 
BioLegend) on denervation-induced muscle loss, 8-wk-old C57BL/6 mice 
were used. 2 d after denervation, the mice were treated by intraperitoneal 
injections of either 200 µg/mouse MTW1 antibody or 200 µg/ml isotype 
control every third day (total of three injections). After 24 h of final injec-
tion, the mice were sacrificed, and hind limb muscles were isolated for   
histological experiments.
Electroporation of plasmid DNA in TA muscle
The injection of plasmid DNA into TA muscle of mice and electroporation 
were performed according to a protocol as previously described (Schertzer 
et al., 2006). In brief, pNF-B–Luc (Takara Bio Inc.) and pRL-TK renilla   
luciferase (Promega) were prepared using an endotoxin-free kit (QIAGEN) 
and suspended in sterile saline solution in a 1:10 ratio. Mice were anes-
thetized, and a small portion of TA muscle of both hind limbs was surgically 
exposed and injected with 30 µl of 0.5 U/µl hyaluronidase (EMD). 2 h 
later, plasmid DNA (50 µg in 25 µl saline) was injected in TA muscle, and 
1 min after plasmid DNA injection, a pair of platinum plate electrodes was 
placed against the closely shaved skin on either side of the small surgical 
incision (such that the electrodes did not contact the muscle), and electric 
pulses were delivered transcutaneously. Three 20-ms square-wave pulses of 
1-Hz frequency at 75V/cm were generated using a stimulator (model S88; 
Grass Technologies) and delivered to the muscle. The polarity was then   
reversed, and a further three pulses were delivered to the muscle. After 
electroporation, the wound was closed with surgical clips, and mice were 
returned to their cages and fed a standard diet. 3 d after electroporation, 
the left hind limb was denervated, whereas the right side was only sham 
operated. Finally, after 10 d of denervation, the mice were sacrificed,   
TA muscle was isolated, and muscle extracts made were used for measure-
ment of luciferase and renilla activity using a Dual-luciferase reporter assay 
system (Promega).
RNA isolation and QRT-PCR
RNA isolation and QRT-PCR were performed using a method as previously 
described (Dogra et al., 2006, 2007b). In brief, RNA was extracted from 
homogenized tissues using TRIZOL reagent (Invitrogen) and an RNeasy 
Mini kit (QIAGEN) according to the manufacturers’ protocol. The quantifica-
tion of mRNA expression was performed using the SYBR green dye method 
on a sequence detection system (model 7300; Applied Biosystems). 1 µg 
of purified RNA was used to synthesize first strand cDNA by reverse transcrip-
tion system using oligo (dT) primer (Applied Biosystems) and the Omniscript 
reverse transcription kit (QIAGEN). The first strand cDNA reaction (0.5 µl) was 
subjected  to  real-time  PCR  amplification  using  gene-specific  primers. 
The sequence of primers used is described in Table S1.
Approximately 25 µl of reaction volume was used for the real-time 
PCR assay that consisted of 2× of 12.5 µl Brilliant SYBR green QPCR master 
mix (Applied Biosystems), 400 nM of primers (0.5 µl each from the stock), 
11 µl water, and 0.5 µl of template. The thermal conditions consisted of an 
initial denaturation at 95°C for 10 min, followed by 40 cycles of denatur-
ation at 95°C for 15 s, annealing and extension at 60°C for 1 min, and, 
for a final step, a melting curve of 95°C for 15 s, 60°C for 15 s, and 95°C 
for 15 s. All reactions were performed in duplicate to reduce variation. 
TWEAK–Fn14 pathway specifically up-regulates the expres-
sion  of  the  components  of  the  ubiquitin–proteasome  system   
(e.g., MuRF1) in denervated skeletal muscle.
The TWEAK–Fn14 pathway provides  
a novel signaling mechanism to  
regulate skeletal muscle mass under 
denervation conditions
These data highlight a previously undiscovered and surprising 
mechanism for modulating skeletal muscle atrophy. The fact that 
the Fn14 receptor but not TWEAK itself is up-regulated under 
atrophy conditions suggests a mechanism in which muscle 
creates a permissive setting for atrophy by modulating the 
TWEAK receptor. Because TWEAK itself is not perturbed, the 
data  suggest  that  the  receptor’s  expression  is  limiting  for 
TWEAK to function. It is noteworthy that in younger animals, 
TWEAK overexpression is not sufficient to cause atrophy, but it 
is able to increase muscle loss under atrophy conditions. Because 
the  TWEAK  receptor  Fn14  is  up-regulated  by  denervation,   
this adds further data for the inference that Fn14 levels are lim-
iting, and therefore, TWEAK requires Fn14 up-regulation to in-
duce atrophy. Finally, one can always push back the definition 
of the term trigger. For example, although the current study 
identifies TWEAK–Fn14 signaling as being necessary to up-
regulate NF-B–MuRF1-induced proteolysis in atrophy condi-
tions, one can then enquire as to the mechanism by which 
denervation up-regulates Fn14. This is also an area of interest 
for future investigation.
The TWEAK–Fn14 pathway as a potential 
target to counter disuse-related skeletal 
muscle atrophy
This study marks an initial attempt to determine whether an   
inflammatory cytokine is involved in disuse-related skeletal 
muscle atrophy. The identification of the TWEAK–Fn14 dyad 
as a mediator of denervation-induced muscle atrophy suggests 
that inhibition of this pathway may be helpful under denervation 
and perhaps disuse conditions, especially because the deletion 
of TWEAK was sufficient to maintain muscle strength in addi-
tion to mass. Although Fn14 is not up-regulated in every setting 
of muscle atrophy, future studies will help to determine the full 
range of clinically relevant settings in which the TWEAK–
Fn14 pathway is operative and in which inhibition of this path-
way is sufficient to preserve functional muscle.
Materials and methods
Animal models
Transgenic mice expressing full-length TWEAK cDNA under the control of 
muscle CK promoter were generated as described previously (Dogra et al., 
2007a). TWEAK-KO mice were provided by A. Ashkenazi (Genentech 
South San Francisco, CA; Maecker et al., 2005). All of the mice were in 
the C57BL/6 background, and their genotype was determined by PCR 
from tail DNA.
To induce atrophy, 12-wk-old mice were either casted or denervated 
for 3–7 d, as previously described (Bodine et al., 2001a). To study hyper-
trophy, the casted muscles were allowed to recover for 1 wk after the casts 
were removed. Also, as an additional model of hypertrophy, animals were 
treated with clenbuterol for 1 wk, as described previously (Kline et al., 2007). 
Sciatic denervation was performed by anesthetizing the mice with an 847 TWEAK regulates denervation-induced muscle atrophy • Mittal et al.
596–conjugated secondary antibodies (1:3,000; Invitrogen) were used 
for detection. Fiber CSA was analyzed in H&E- or laminin-stained soleus 
or TA muscle sections. For each muscle, the distribution of fiber CSA was   
calculated by analyzing 200–500 myofibers as described previously (Dogra   
et al., 2007a; Li et al., 2009b).
Skeletal muscle functional analysis
The  skeletal  muscle  force  production  in  isometric  contraction  was  per-
formed as previously described (Li et al., 2009b). In brief, soleus muscle 
from control or denervated hind limb of mice was rapidly excised and 
placed in Krebs-Ringer solution. The muscle was mounted between a 
Fort25 force transducer (World Precision Instruments) and a micromanipu-
lator device in a temperature controlled myobath (World Precision Instru-
ments).  The  muscle  was  positioned  between  platinum  wire  stimulating 
electrodes and stimulated to contract isometrically using electrical field 
stimulation (supramaximal voltage, 1.2-ms pulse duration) from the S88 
stimulator. In each experiment, muscle length was adjusted to optimize 
twitch force (optimal length, Lo). The muscle was rested for 15 min before 
the tetanic protocol was started. The output of the force transducer was   
recorded in a computer using Lab-Trax-4 software (World Precision Instru-
ments).  To  evaluate  a  potentially  different  frequency  response  between 
groups, tetani were assessed by sequential stimulation at 80, 120, 150, 
220, and 300 Hz with a 2-min rest in between.
Statistical analysis
Results are expressed as mean ± SD. The Student’s t test or analysis of   
variance was used to compare quantitative data populations with normal 
distributions and equal variance. A value of P < 0.05 was considered sta-
tistically significant unless otherwise specified.
Online supplemental material
Fig. S1 shows the expression of collagen I, II, and III in soleus muscle of 
control and TWEAK-Tg mice analyzed by fluorescence microscopy and 
Western blotting. Fig. S2 examines the concentration of macrophages in 
soleus muscle of control, TWEAK-Tg, and TWEAK-KO mice. Fig. S3 ex-
amines the activation of the Akt signaling pathway in denervated skeletal 
muscle of control, transgenic, and knockout mice. Fig. S4 demonstrates the 
expression of autophagy-related genes in denervated skeletal muscle of 
control, transgenic, and knockout mice. Table S1 describes the sequence of 
the primers used in QRT-PCR assays. Online supplemental material is avail-
able at http://www.jcb.org/cgi/content/full/jcb.200909117/DC1.
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